Clinical Trials

Inclusion Criteria:

• Specimen must consist of de-identified FFPE human NSCLC tissue;

• Specimen must contain sufficient tumor tissue of consistent morphology throughout the tissue block (based on the RTD pathologists’ reviews of bracketing slides stained with H&E); and

• Specimen must exhibit consistent TROP2 expression throughout the tissue block (based on the RTD pathologists’ reviews of bracketing slides stained with the VENTANA TROP2 (EPR20043) Rabbit Monoclonal Antibody, RUO)

Exclusion Criteria:

• The amount of tumor tissue is insufficient to cut and mount the required number of tissue sections for use in the study;

• Specimen exhibits significant tumor tissue loss throughout the tissue block (based on the RTD pathologists’ review);

• Specimen is a fine needle aspirate or cytology specimen; or

• Specimen consists of tissue that has been decalcified

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 05/09/2025. Questions regarding updates should be directed to the study team contact.